0,1,2,3,4,5,6
Table 7.5:   Subgroup analysis of first-line immune checkpoint inhibitor combinations in RCC patients,,,,,,
Study,N (  ITT),Therapy,N   (sRCC),PFS (mo.)  Median (95% CI)   HR,OS (mo.)  Median (95% CI)  HR,ORR (%)  (95% CI)
KEYNOTE-426  NCT02853331  Median    follow-up    12.8 mo. [540],861,PEMBRO + AXI  SUN,51  54,NR  8.4   HR: 0.54   (0.29–1.00),NR  NR  HR: 0.58   (0.21–1.59),58.8  31.5
"JAVELIN 101   NCT02684006  [541, 542]",886,AVE + AXI  SUN,47  61,7.0 (5.3–13.8)   4.0 (2.7–5.7)   HR 0.57    (0.33–1.00),NA,46.8 (32.1–61.9)   21.3 (11.9–33.7)
IMmotion151  NCT02420821  Median   follow-up   13 to 17 mo.  [543],915,ATEZO + BEV  SUN,68  74,"8.3 (5.4, 12.9)  5.3 (3.3, 6.7)  HR: 0.52    (0.34–0.79)","21.7 (15.3, NE)  15.4 (10.4, 19.5)  0.64 (0.41, 1.01)",49 (36–1)  14 (7–23)
Checkmate   214  NCT02231749  Median   follow-up of   30 mo. [544],1096,NIVO + IPI  SUN,60  52,8.4 (5.2–24.0)  4.9 (4.0–7.0)  HR: 0.61   (0.38–0.97),31.2 (23.0–NE)  13.6 (7.7–20.9)  HR: 0.55    (0.33–0.90),56.7 (43.2–69.4)  19.2 (9.6–32.5)
CheckMate   9ER   NCT03141177  Median   follow-up    16 mo. [545],651,NIVO + CABO  SUN,34  41,10.3 (5.6–19.4)  4.2 (2.6–8.3)  HR: 0.42   (0.23–0.74),NR (22.8–NE)  19.7 (8.9–29.5)  HR: 0.36   (0.17–0.79),55.9 (37.9–72.8)  22.0 (10.6–37.6)
"CLEAR  NCT02811861  Median    follow-up   27 mo. [527,   546]",712,PEMBRO + LEN  SUN,28  21,11.1  5.5  HR: 0.39   (0.18–0.84),NE  NE  HR: 0.91   (0.32–2.58),60.7  23.8
